
Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.

Prof Alan Irvine presents the latest clinical and real-world evidence supporting the potential for disease modification in atopic dermatitis, at EADV 2025.

An interactive tool highlighting the disease burden, impact and management of prurigo nodularis throughout the patient journey before diagnosis, during diagnosis and during treatment.
Prof. Vibeke Backer provides an insightful presentation on the association of type 2 inflammation and the pathogenesis and management of severe and uncontrolled CRSwNP.
Join global experts for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.
Join Prof. Sietze Reitsma for an insightful presentation that will delve into identifying and leveraging key characteristics to optimize patient management and treatment outcomes.

Highlights from the ADVENT symposium at the 2023 World Congress of Dermatology in Singapore.
Join ADVENT at the Digestive Disease Week 2024 Congress and visit the Sanofi and Regeneron Medical Booth # 1707.

Exploring the role of type 2 inflammation and the neuroimmune axis in CSU, and how emerging therapeutics are targeting key molecules in these pathways.

In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang discusses how to identify pediatric patients with AD uncontrolled with topical therapies, considerations for the next step in care for these patients, and the potential benefits of early intervention with systemic treatment

This video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria features Drs Christine Bangert, Mark Boguniewicz, and Perla Lansang as they discuss the inflammatory processes driven by type 2 cytokines that lead to AD and atopic comorbidities, the multidimensional and cumulative disease burden associated with AD and its comorbidities, and the current and emerging treatment options for children with AD uncontrolled with topical therapy